Experts red-flag cancer drug price cuts as patented therapies see zero relief, markups exceed benchmark
Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
